HYPER: pre-clinical device for spatially-confined magnetic particle hyperthermia.
Magnetic particle hyperthermia
design verification
spatially confined heating
Journal
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
ISSN: 1464-5157
Titre abrégé: Int J Hyperthermia
Pays: England
ID NLM: 8508395
Informations de publication
Date de publication:
2023
2023
Historique:
pmc-release:
24
10
2024
medline:
26
10
2023
pubmed:
25
10
2023
entrez:
24
10
2023
Statut:
ppublish
Résumé
Magnetic particle hyperthermia is an approved cancer treatment that harnesses thermal energy generated by magnetic nanoparticles when they are exposed to an alternating magnetic field (AMF). Thermal stress is either directly cytotoxic or increases the susceptibility of cancer cells to standard therapies, such as radiation. As with other thermal therapies, the challenge with nanoparticle hyperthermia is controlling energy delivery. Here, we describe the design and implementation of a prototype pre-clinical device, called HYPER, that achieves spatially confined nanoparticle heating within a user-selected volume and location. Spatial control of nanoparticle heating was achieved by placing an AMF generating coil (340 kHz, 0-15 mT), between two opposing permanent magnets. The relative positions between the magnets determined the magnetic field gradient (0.7 T/m-2.3 T/m), which in turn governed the volume of the field free region (FFR) between them (0.8-35 cm We verified the performance of the HYPER to design specifications by independently heating two nanoparticle-rich areas of a phantom placed within the volume occupied by the AMF heating coil.
Identifiants
pubmed: 37875265
doi: 10.1080/02656736.2023.2272067
pmc: PMC10624165
mid: NIHMS1939134
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2272067Subventions
Organisme : NCI NIH HHS
ID : R01 CA247290
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257557
Pays : United States
Organisme : NCI NIH HHS
ID : R44 CA285064
Pays : United States
Références
Int J Hyperthermia. 2018 Jun;34(4):373-381
pubmed: 28758530
Eur Urol. 2007 Dec;52(6):1653-61
pubmed: 17125906
Int J Hyperthermia. 2020 Dec;37(3):59-75
pubmed: 33426997
Int J Hyperthermia. 2013 Dec;29(8):715-29
pubmed: 24131317
Theranostics. 2020 Feb 10;10(7):2965-2981
pubmed: 32194849
Nano Lett. 2017 Mar 8;17(3):1648-1654
pubmed: 28206771
J Mater Chem B. 2022 Jul 20;10(28):5364-5374
pubmed: 35775939
Int J Hyperthermia. 2015 Jun;31(4):359-74
pubmed: 25811736
ACS Nano. 2018 Apr 24;12(4):3699-3713
pubmed: 29570277
IEEE Trans Biomed Eng. 1994 Jan;41(1):17-28
pubmed: 8200664
ACS Appl Mater Interfaces. 2014 Oct 8;6(19):16867-79
pubmed: 25204363
Int J Hyperthermia. 2019 Nov;36(sup1):47-63
pubmed: 31795835
Nano Lett. 2012 Jul 11;12(7):3716-21
pubmed: 22720795
Front Therm Eng. 2023;3:
pubmed: 36945684
IEEE Trans Med Imaging. 2011 Sep;30(9):1581-90
pubmed: 21402508
Int J Hyperthermia. 2020;37(1):1-14
pubmed: 31918595
Int J Hyperthermia. 2020 Dec;37(3):108-119
pubmed: 33426990
Adv Drug Deliv Rev. 2019 Jan 1;138:293-301
pubmed: 30552918
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7093s-7103s
pubmed: 16203808
Cancer Growth Metastasis. 2017 Sep 18;10:1179064417730559
pubmed: 29403306
J Neurooncol. 2011 Jun;103(2):317-24
pubmed: 20845061
Nano Lett. 2019 Jul 10;19(7):4287-4296
pubmed: 31132270
Int J Hyperthermia. 2019;36(1):712-720
pubmed: 31345068
Int J Hyperthermia. 2013;29(2):106-20
pubmed: 23402327
J Appl Phys. 2023 Jan 28;133(4):044302
pubmed: 36718210
Nanomedicine (Lond). 2012 Nov;7(11):1697-711
pubmed: 22830502
Chemistry. 2021 Oct 19;27(58):14535-14542
pubmed: 34403531
Phys Med Biol. 2017 May 7;62(9):3483-3500
pubmed: 28032621
Int J Hyperthermia. 2019;36(1):115-129
pubmed: 30541354
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1779
pubmed: 35238181